Reverse greenshoe

Frontier Announces Pricing of Initial Public Offering

Retrieved on: 
Thursday, April 1, 2021
Financial markets, Financial economics, Finance, Corporate finance, Stock market, Initial public offering, Stock, Underwriting, Public offering, Greenshoe, Reverse greenshoe

DENVER, March 31, 2021 (GLOBE NEWSWIRE) -- Frontier Group Holdings, Inc. (Frontier) today announced the pricing of its initial public offering of 30 million shares of its common stock at a price to the public of $19.00 per share.

Key Points: 
  • DENVER, March 31, 2021 (GLOBE NEWSWIRE) -- Frontier Group Holdings, Inc. (Frontier) today announced the pricing of its initial public offering of 30 million shares of its common stock at a price to the public of $19.00 per share.
  • The offering consists of 15 million shares of common stock offered by Frontier and 15 million shares of common stock to be sold by certain of Frontiers existing stockholders.
  • A selling stockholder has granted the underwriters a 30-day option to buy an additional 4.5 million shares of common stock from such selling stockholder at the initial public offering price, less the underwriting discount and commissions.
  • Frontier will receive net proceeds of approximately $266 million after deducting the underwriting discount and commissions and estimated offering expenses.

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

Retrieved on: 
Wednesday, March 24, 2021
Stock market, Initial public offering, Finance, Corporate finance, Actuarial science, Underwriting, Option, Money, Corporations, Greenshoe, Reverse greenshoe

All of the ordinary shares in the offering were sold by Prothena.

Key Points: 
  • All of the ordinary shares in the offering were sold by Prothena.
  • In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 525,000 of its ordinary shares.
  • Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $67.8 million, after deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriters option to purchase additional ordinary shares.
  • The offering is expected to close on March 26, 2021, subject to customary closing conditions.

Frontier Announces Launch of Initial Public Offering

Retrieved on: 
Tuesday, March 23, 2021
Financial markets, Financial economics, Finance, Corporate finance, Stock market, Initial public offering, Stock, Public offering, Greenshoe, Reverse greenshoe

DENVER, March 23, 2021 (GLOBE NEWSWIRE) -- Frontier Group Holdings, Inc. (Frontier) today announced the launch of its initial public offering of 30 million shares of its common stock.

Key Points: 
  • DENVER, March 23, 2021 (GLOBE NEWSWIRE) -- Frontier Group Holdings, Inc. (Frontier) today announced the launch of its initial public offering of 30 million shares of its common stock.
  • The offering consists of 15 million shares of common stock offered by Frontier and 15 million shares of common stock to be sold by certain of Frontiers existing stockholders.
  • A selling stockholder intends to grant the underwriters a 30-day option to buy an additional 4.5 million shares of common stock from such selling stockholder at the initial public offering price, less the underwriting discount and commissions.
  • The initial public offering price is currently expected to be between $19 and $21 per share.

ClearPoint Neuro Announces Closing of Public Offering of 2,127,660 Shares of Common Stock

Retrieved on: 
Tuesday, February 23, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Initial public offering, Stock, NASDAQ, Public offering, Greenshoe, Reverse greenshoe

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the closing of its previously disclosed public offering of common stock.

Key Points: 
  • IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the closing of its previously disclosed public offering of common stock.
  • The total number of shares of common stock sold was 2,127,660, composed of 1,850,140 shares of common stock initially offered at a public offering price of $23.50 per share and an additional 277,520 shares of common stock sold pursuant to the exercise of the underwriters' option to purchase additional shares at the price of $22.09 per share.
  • The net proceeds to the Company from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $46.8 million.
  • We are very pleased with the result and closing of this recent stock offering, commented Joe Burnett, the Companys President and Chief Executive Officer.

Generation Bio Announces Pricing of Public Offering

Retrieved on: 
Thursday, January 7, 2021
Financial markets, Financial economics, Finance, Initial public offering, Corporate finance, Stock market, Underwriting, Stock, Public offering, Greenshoe, Reverse greenshoe

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per share.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per share.
  • In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less the underwriting discount and commissions.
  • All of the shares are being offered by Generation Bio.
  • The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Generation Bio, are expected to be approximately $196.0 million, excluding any exercise of the underwriters option to purchase additional shares.

Seer Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, December 4, 2020
Financial markets, Financial economics, Finance, Stock market, Corporate finance, Initial public offering, Underwriting, Stock, Public offering, Greenshoe, Reverse greenshoe

REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced the pricing of its initial public offering of 9,210,527 shares of Class A common stock at a public offering price of $19.00 per share.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced the pricing of its initial public offering of 9,210,527 shares of Class A common stock at a public offering price of $19.00 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Seer, are expected to be $175 million, excluding any exercise of the underwriters option to purchase additional shares.
  • The offering is expected to close on December 8, 2020, subject to the satisfaction of customary closing conditions.
  • In addition, Seer has granted the underwriters a 30-day option to purchase up to an additional 1,381,579 shares of Class A common stock at the initial public offering price, less the underwriting discounts and commissions.

BeiGene Announces Pricing of Public Offering by Selling Shareholders

Retrieved on: 
Wednesday, December 2, 2020
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Finance, Financial markets, Money, Initial public offering, Subprime mortgage crisis, Stock market, Goldman Sachs, Underwriting, ADSS, BeiGene, Reverse greenshoe, Rights issue

In addition, the Selling Shareholders have granted the underwriter a 30-day option to purchase up to an additional 151,154 ADSs at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, the Selling Shareholders have granted the underwriter a 30-day option to purchase up to an additional 151,154 ADSs at the public offering price, less underwriting discounts and commissions.
  • BeiGene will not receive any of the proceeds from the sale of the shares offered by the Selling Shareholders but will bear certain expenses incident to this offering (excluding underwriting discounts and commissions).
  • The offering is expected to close on December 4, 2020, subject to customary closing conditions.
  • Goldman Sachs & Co. LLC is acting as the underwriter for the offering.

DGAP-News: fashionette AG: Post-Stabilisation disclosure - Partial exercise of the Greenshoe Option

Retrieved on: 
Friday, November 27, 2020
Stock market, Initial public offering, Greenshoe, Prospectus, Security, Reverse greenshoe

Disclosure of the partial exercise of the Greenshoe Option in accordance with Article 8 lit.

Key Points: 
  • Disclosure of the partial exercise of the Greenshoe Option in accordance with Article 8 lit.
  • The Greenshoe Option was exercised by the stabilisation manager in the amount of 296,346 no-par value ordinary shares of the Issuer.
  • This disclosure does neither constitute an offer of securities to the public nor a prospectus within the meaning of the Prospectus Regulation.
  • Any investment activity to which this disclosure relates will only be available to and will only be engaged with, relevant persons.

Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock

Retrieved on: 
Thursday, October 29, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Financial markets, Stock market, Financial economics, Finance, Corporate finance, Initial public offering, Stock, Greenshoe, Reverse greenshoe

Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share.

Key Points: 
  • Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share.
  • In addition, Forte has granted to the underwriters a 30-day option to purchase up to an additional 210,526 shares of common stock at the public offering price of $28.50 per share, less underwriting discounts and commissions.
  • All of the shares of common stock are being offered by Forte.
  • The offering is expected to close on or about November 2, 2020, subject to customary closing conditions.

Phreesia Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, October 23, 2020
Data management, Health, Technology, Other Technology, Other Health, Managed care, Software, Financial markets, Financial economics, Finance, Corporate finance, Stock market, Initial public offering, Underwriting, Public offering, Stock, Greenshoe, Reverse greenshoe

Phreesia, Inc. (Phreesia or the Company) (NYSE: PHR), a leading patient intake management platform, announced today the closing of the underwritten public offering of 5,750,000 shares of its common stock (the Offering), all of which were sold by the Company, which includes the full exercise of the underwriters option to purchase 750,000 additional shares of common stock.

Key Points: 
  • Phreesia, Inc. (Phreesia or the Company) (NYSE: PHR), a leading patient intake management platform, announced today the closing of the underwritten public offering of 5,750,000 shares of its common stock (the Offering), all of which were sold by the Company, which includes the full exercise of the underwriters option to purchase 750,000 additional shares of common stock.
  • The shares were sold at a public offering price of $32.00 per share and were purchased by the underwriters from the Company at the public offering price, less the underwriting discount.
  • Phreesia received net proceeds from the offering of approximately $174.4 million after deducting underwriting discounts and estimated offering expenses.
  • J.P. Morgan and William Blair acted as joint book-running managers for the Offering and as representatives of the underwriters.